Speakers / Instructors:

• Giannoula Lakka Klement, MD, FRCP(C)
  Center of Cancer Systems Biology; Steward Research & Specialty Projects Corp.; St. Elizbeth's Medical Center; Tufts University School of Medicine; Newman-Lakka Institute for Personalized Cancer Care
  Boston, Massachusetts, USA
   
  
• Nicolas André MD, PhD
  INSERM, UMR 911, Aix-Marseille University, Medicine School; Pediatric Oncology and Hematology Unit, Hôpital pour Enfants de la Timone; Assistance Publique-Hôpitaux de Marseille; Metronomics Global Health Initiative
  Marseille, France
   
  
• Barton Kamen, MD, PhD
  The Cancer Institute of New Jersey; Robert Wood Johnson Medical School
  New Brunswick, New Jersey, USA
   
  
• Eddy Pasquier, PhD
  Children's Cancer Institute Australia for Medical Research; University of New South Wales
  Sydney, Australia
  Metronomics Global Health Initiative
   
  
• David J. Waxman, PhD
  Department of Biology, Boston University; Boston University Cancer Center; Boston University School of Medicine
  Boston, Massachusetts, USA
   
  

• Philip Hahnfeldt, PhD
  Center of Cancer Systems Biology; Steward Research & Specialty Projects Corp.; St. Elizabeth's Medical Center; Tufts University School of Medicine
  Boston, Massachusetts, USA
   
  
• Sébastien Benzekry, PhD
  Center of Cancer Systems Biology; Steward Research & Specialty Projects Corp.; St. Elizabeth's Medical Center; Tufts University School of Medicine
  Boston, Massachusetts, USA
   
  
• Urszula Ledzewicz, PhD
  Department of Mathematics and Statistics, Southern Illinois University Edwardsville
  Boston, Massachusetts, USA
   
  
• J. Carl Panetta, PhD
  Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital
  Memphis, Tennessee, USA
   
  
• Heinz Schaettler, PhD
  Department of Electrical and Systems Engineering, Washington University
  St. Louis, Missouri, USA
   
  

Guest Speaker:

• Larry Norton, MD
  Director, Evelyn H. Lauder Breast Center and Norna S. Sarofim Chair in Clinical Oncology, Memorial Sloan-Kettering Cancer Center
  New York, New York, USA
  

 

Selected speaker publications on the topic of tumor metronomics:

• André N, Padovani L, Pasquier E. Metronomic scheduling of anticancer treatment: the next generation of multitarget therapy? Future Oncol. 2011 Mar;7(3):385-94. PubMed PMID: 21417902.
   
  
• Benzekry S, André N, Benabdallah A, Ciccolini J, Faivre C, Hubert F, Barbolosi D. Modeling the impact of anticancer agents on metastatic spreading. Math Model Nat Phenom. 2012 Jan;7(1):306-36. Epub 2012 Jan 25. DOI: http://dx.doi.org/10.1051/mmnp/20127114
   
  
• d'Onofrio A, Ledzewicz U, Maurer H, Schättler H. On optimal delivery of combination therapy for tumors. Math Biosci. 2009 Nov;222(1):13-26. Epub 2009 Aug 23. PubMed PMID: 19706298.
   
  
• Doloff JC, Waxman DJ. VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression. Cancer Res. 2012 Mar 1;72(5):1103-15. Epub 2012 Jan 11. PubMed PMID: 22237627.
   
  
• Frost P, Kamen BA. The bullseye of cancer therapy: a moving target. Curr Opin Pharmacol. 2003 Aug;3(4):335-7. PubMed PMID: 12901940.
   
  
• Hahnfeldt P, Folkman J, Hlatky L. Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. J Theor Biol. 2003 Feb 21;220(4):545-54. PubMed PMID: 12623285.
   
  
• Hahnfeldt P, Hlatky L. Resensitization due to redistribution of cells in the phases of the cell cycle during arbitrary radiation protocols. Radiat Res. 1996 Feb;145(2):134-43. PubMed PMID: 8606922.
   
  
• Hahnfeldt P, Hlatky L. Cell resensitization during protracted dosing of heterogeneous cell populations. Radiat Res. 1998 Dec;150(6):681-7. PubMed PMID: 9840188.
   
  
• Hahnfeldt P, Panigrahy D, Folkman J, Hlatky L. Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res. 1999 Oct 1;59(19):4770-5. PubMed PMID: 10519381.
   
  
• Kamen BA, Glod J, Cole PD. Metronomic therapy from a pharmacologist's view. J Pediatr Hematol Oncol. 2006 Jun;28(6):325-7. Review. PubMed PMID: 16794497.
   
  
• Kamen BA, Rubin E, Aisner J, Glatstein E. High-time chemotherapy or high time for low dose. J Clin Oncol. 2000 Aug;18(16):2935-7. Review. PubMed PMID: 10944125.
   
  
• Kieran MW, Turner CD, Rubin JB, Chi SN, Zimmerman MA, Chordas C, Klement G, Laforme A, Gordon A, Thomas A, Neuberg D, Browder T, Folkman J. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol. 2005 Nov;27(11):573-81. PubMed PMID: 16282886.
   
  
• Kerbel RS, Klement G, Pritchard KI, Kamen B. Continuous low-dose anti-angiogenic/ metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol. 2002 Jan;13(1):12-5. PubMed PMID: 11863092.
   
  
• Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest. 2000 Apr;105(8):R15-24. PubMed PMID: 10772661.
   
  
• Klement G, Huang P, Mayer B, Green SK, Man S, Bohlen P, Hicklin D, Kerbel RS. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res. 2002 Jan;8(1):221-32. PubMed PMID: 11801563.
   
  
• Ledzewicz U, Marriott J, Maurer H, Schättler H. Realizable protocols for optimal administration of drugs in mathematical models for anti-angiogenic treatment. Math Med Biol. 2010 Jun;27(2):157-79. PubMed PMID: 20513667.
   
  
• Ledzewicz U, Schättler H. Optimal and suboptimal protocols for a class of mathematical models of tumor anti-angiogenesis. J Theor Biol. 2008 May 21;252(2):295-312. Epub 2008 Feb 16. PubMed PMID: 18371982.
   
  
• Ma J, Waxman DJ. Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther. 2008 Dec;7(12):3670-84. Review. PubMed PMID: 19074844.
   
  
• Panetta JC, Schaiquevich P, Santana VM, Stewart CF. Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma. Clin Cancer Res. 2008 Jan 1;14(1):318-25. PubMed PMID: 18172284.
   
  
• Pasquier E, Kavallaris M, André N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol. 2010 Aug;7(8):455-65. Epub 2010 Jun 8. Review. PubMed PMID: 20531380.
   
• Weitman SD, Glatstein E, Kamen BA. Back to the basics: the importance of concentration x time in oncology. J Clin Oncol. 1993 May;11(5):820-1. PubMed PMID: 8487045.
   

Other speaker-recommended publications from the field:

• Reynolds AR. Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer. Dose Response. 2010 Apr 23;8(3):253-84. PubMed PMID: 20877487.
   
  
• Zitvogel L, Apetoh L, Ghiringhelli F, André F, Tesniere A, Kroemer G. The anticancer immune response: indispensable for therapeutic success? J Clin Invest. 2008 Jun;118(6):1991-2001. Review. PubMed PMID: 18523649.